Skip to main content
Midas Edge

Lexeo Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 14, 2025

LXEO$3.06-2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity (unaudited)

Condensed Statements of Stockholders’ Equity

(Unaudited, in thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders'
SharesAmountStockCapitalIncome (Loss)DeficitEquity
Balances at December 31, 202433,071,261$3$(17)$397,132$(103)$(280,173)$116,842
Issuance of common stock upon vesting and settlement of restricted stock units52,446------
Issuance of common stock under 2023 ESPP65,342--170--170
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase2,816--13--13
Unrealized comprehensive gain on investments----49-49
Stock-based compensation expense---3,697--3,697
Net loss-----(32,656)(32,656)
Balances at March 31, 202533,191,865$3$(17)$401,012$(54)$(312,829)$88,115
Issuance of common stock upon vesting and settlement of restricted stock units14,097------
Issuance of common stock, pre-funded warrants and warrants to purchase common stock upon May 2025 Private Placement Offering, net of commissions and offering costs of $6,91720,790,1202-73,080--73,082
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase2,410--12--12
Unrealized comprehensive gain on investments----41-41
Stock-based compensation expense---3,071--3,071
Net loss-----(26,103)(26,103)
Balances at June 30, 202553,998,492$5$(17)$477,175$(13)$(338,932)$138,218
Accumulated
Additional · Other · Total
Common Stock · Treasury · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Stock · Capital · Income (Loss) · Deficit · Equity
Balances at December 31, 202326,646,378$3$-$295,372$-$(181,840)$113,535
Exercise of stock options942--10--10
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase1,916--3--3
Issuance of common stock upon March 2024 Private Placement Offering, net of commissions and offering costs of $6,2466,278,905--88,753--88,753
Stock-based compensation expense---2,331--2,331
Net loss-----(21,682)(21,682)
Balances at March 31, 202432,928,141$3$-$386,469$-$(203,522)$182,950
Exercise of stock options108,912--419--419
Amounts reclassified from deposit liabilities upon the vesting of early-exercised stock options previously subject to repurchase5,849--26--26
Additional offering costs incurred related to issuance of common stock upon private placement offering---(42)--(42)
Treasury stock repurchase(2,991)-(13)---(13)
Stock-based compensation expense---2,846--2,846
Net loss-----(21,238)(21,238)
Balances at June 30, 202433,039,911$3$(13)$389,718$-$(224,760)$164,948
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.